US-based pharmaceutical company Calyptus Pharmaceuticals, Inc. announced on Wednesday that the US Food and Drug Administration granted approval to an Abbreviated New Drug Application (ANDA) for a generic version of Brovana (Arformoterol Tartrate inhalation solution, EQ 0.015mg Base/2ml) to Calyptus' partner - VistaPharm, Inc.

Arformoterol Tartrate inhalation solution, EQ 0.015mg Base/2ml has been co-developed in collaboration with VistaPharm.

The product is intended for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, which includes chronic bronchitis and emphysema. It is for use by nebulisation only.